Maintaining awareness of the latest medical literature enables clinicians to enhance diagnostic precision and integrate emerging evidence into routine practice. Consistent engagement with current research strengthens clinical decision-making and, for patients, facilitates improved outcomes and supports delivery of high-quality, evidence-based care.

Today, we've curated a selection of recently published oncology articles. Today's oncology-focused rundown is divided into three sections for convenience: glioblastoma, renal cell carcinoma (RCC), and lymphoma. Some of the included associated descriptions were edited for clarity and brevity. All articles were published within the past month.

Glioblastoma

Cs-131 Collagen Tile Brachytherapy for Recurrent Glioblastoma: Treatment Outcomes and Toxicity

  • Practical Radiation Oncology, December 2025
  • Description: Recurrence in glioblastoma (GBM) is common, and success of salvage strategies including re-resection and re-irradiation are limited. Brachytherapy with Cs-131 collagen tiles enables intraoperative focal dose intensification with rapid dose fall-off and limited normal-brain radiation exposure. [Researchers] report outcomes of Cs-131 collagen tile implantation at resection for recurrent GBM.
  • Summary
  • Full Text

Interplay Between Hypoxia-Inducible Factors and Apoptosis in Glioblastoma

  • Biochemical Pharmacology, December 2025
  • Description: In this review, [researchers summarize] recent advances in [the overall] understanding of the HIF–apoptosis axis in GBM and discuss potential therapeutic strategies that target this molecular crosstalk.
  • Summary
  • Full Text

Potential Therapeutic Targeting of BKca Channels in Glioblastoma Treatment

  • Molecular Oncology, December 2025
  • Description: This review summarizes current insights into the role of BK and mitoBK channels in glioblastoma biology, their potential classification as oncochannels, and the emerging pharmacological strategies targeting these channels, emphasizing the translational challenges in developing BK-directed therapies for glioblastoma treatment.
  • Summary
  • Full Text

INSM1 Governs a Neuronal Progenitor State that Drives Glioblastoma in Human Stem Cell Model

  • Nature Communications, December 2025
  • Description: To investigate how canonical glioblastoma mutations promote functional plasticity, [researchers] developed an isogenic human neural stem cell (NSC) model of glioblastoma by sequential addition of TERT promoter, TP53, and PDGFRA point mutations.
  • Summary
  • Full Text
Renal Cell Carcinoma

PSMA PET in Renal Cell Carcinoma: An Update and Future Aspects

  • Seminars in Nuclear Medicine, December 2025
  • Description: Prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) has recently emerged as a promising molecular imaging tool for renal cell carcinoma, particularly for the clear-cell subtype.
  • Summary
  • Full Text

Age-Related Survival Disparities in Advanced Renal Cell Carcinoma Following Immune Checkpoint Inhibitor Adoption Using SEER and Meta-Analysis

  • Scientific Reports, December 2025
  • Description: This study aimed to evaluate age-related survival outcomes in advanced renal cell carcinoma patients receiving ICI using integrated cohorts.
  • Summary
  • Full Text

Diagnostic Pitfall of Lytic Bone Lesions: A Case of Chromophobe Renal Cell Carcinoma Coexisting With Multiple Myeloma

  • Cureus, November 2025
  • Description: [The authors] report the case of a 66-year-old man diagnosed with chromophobe RCC who presented with persistent back pain and was ultimately diagnosed with coexisting multiple myeloma.
  • Summary
  • Full Text
Lymphoma Topics

Tafasitamab, Lenalidomide, and Rituximab in Relapsed or Refractory Follicular Lymphoma (inMIND): A Global, Phase 3, Randomised Controlled Trial

  • Lancet, December 2025
  • Description: Lenalidomide plus rituximab is a commonly used immunotherapy combination in patients with relapsed or refractory follicular lymphoma. [Researchers] aimed to assess the efficacy and safety of adding tafasitamab, a CD19-targeted Fc-enhanced monoclonal antibody, to lenalidomide and rituximab in this setting.
  • Summary
  • Full Text

Comprehensive Cytopathologic, Flow Cytometric and Immunocytochemical Analysis of a Challenging Case of Small Cell Variant of Anaplastic Large T-Cell Lymphoma in a Child

  • Cytopathology: Official Journal of the British Society for Clinical Cytology, December 2025
  • Description: The index case report highlights the diagnostic complexities of the small cell variant of anaplastic large cell lymphoma and emphasises the utility of various ancillary techniques like immunophenotyping and fluorescence in situ hybridization, in conjunction with cytomorphology, in confirming such a challenging diagnosis.
  • Summary
  • Full Text

Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

  • Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, December 2025
  • Description: Pirtobrutinib, a highly selective, noncovalent Bruton tyrosine kinase inhibitor (BTKi), has shown efficacy and safety in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who received prior covalent BTKi. [Researchers] report results, to [their] knowledge, from the first randomized head-to-head comparison of pirtobrutinib versus ibrutinib in BTKi-naïve CLL/SLL in both treatment-naïve patients and patients with relapsed/refractory disease.
  • Summary
  • Full Text

Look forward to more journal-focused topics in the coming weeks. 

Sign up for alerts and stay informed on the latest published articles and guidelines.

Copyright © 2025 Guideline Central, all rights reserved.